Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02575963
Other study ID # API-01
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date October 2012
Est. completion date May 2020

Study information

Verified date July 2023
Source Actinium Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is a multicenter, open label Phase I/II trial. 1. Establish the MTD of fractionated doses of Lintuzumab-Ac225 in combination with low dose cytosine arabinoside (Low Dose Ara-C, LDAC) (Phase 1 portion) 2. Determine the response rate (CR + CRp + CRi) to fractionated doses of Lintuzumab-Ac225 alone (Phase 2 portion)


Description:

The study is a multicenter, open label Phase I/II trial. Phase I, dose-escalation: This portion of the overall study uses a 3+3 design to estimate the maximum tolerated dose (MTD). The starting dose level will be 1.0 μCi/Kg of Lintuzumab-Ac225 and 15 μg/Kg unlabeled HuM195 divided into 2 equal fractionated doses (0.5 μCi/Kg and 7.5 μg /Kg + 0.5 μCi/Kg and 7.5 μg /Kg) with the first fraction administered approximately 4 - 7 days after 1 cycle of LDAC (20 mg subQ every 12 h x 10 days administered for cytoreduction) and the second fraction administered 4-7 days after the first fraction. Subjects will then go on to receive up to 11 additional cycles of LDAC or until progression of disease. Three to six patients will be treated at each dose level, and dose escalation will proceed if less than 33% of patients in a cohort experience dose-limiting toxicity. Phase II, efficacy component. The study was designed as a 2- stage minimax design. Patients will be given two infusions of Lintuzumab-Ac225, 4-8 days apart (Day 5-Day 9), initially at the dose level determined to be the MTD in the Phase I portion. The second dose of Lintuzumab-Ac225 may be delayed up to 14 days after the first dose for clinical or scheduling reasons. Response will be initially assessed on or around days 28-42 after the final study drug administration. The primary endpoint (CR+CRp + CRi) will be determined on day 42. Best response will be evaluated from Day 1, Dose 1 until the end of the study.


Other known NCT identifiers
  • NCT01756677

Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date May 2020
Est. primary completion date November 2018
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Phase 1 Major Inclusion Criteria: 1. Untreated AML, including patients with an antecedent hematologic disorder or secondary disease. Patients with prior MDS may have received therapy with immunomodulatory agents or hypomethylating agents for this diagnosis. Patients with other prior cancer diagnoses are allowed as long as they have no measurable disease, are not undergoing active therapy, and have a life expectancy of = 4 months. 2. Patients age =60 years who: 1. Are unwilling to receive intensive (e.g. 7+3) chemotherapy, or 2. Have poor-risk prognostic factors defined as antecedent hematologic disorder, prior chemotherapy or XRT, abnormal karyotype other than t(8;21), inv16, or t(16;16), any karyotype with FLT3-ITD, or presenting WBC>100K, or 3. Have significant comorbidities, that in the judgment of the investigator makes the subject unsuitable for standard dose induction chemotherapy (e.g. anthracycline and infusional cytarabine given as 7+3), or; 4. Any patient age = 70 years. 3. Blast count =20% 4. Greater than 25% of blasts must be CD33 positive. 5. Adequate renal and hepatic function 6. ECOG = 3 Phase 2 Inclusion Criteria: 1. Untreated AML, including patients with an antecedent hematologic disorder or secondary disease. Patients with prior MDS may have received therapy with immunomodulatory agents for this diagnosis. 2. Patients age =60 years who: 1. Patients =60 years unfit to receive intensive (e.g., 7+3) chemotherapy who have: - Congestive heart failure or documented cardiomyopathy with an EF =50%, provided that EF =35% or, - Documented pulmonary disease with DLCO =65% or FEV1 =65%, provided that patients do not require more than 2 L of oxygen per minute or, - Documented liver disease with marked elevation of transaminases >3 x ULN or, - Serum creatinine >1.2 mg/dL 2. Have significant comorbidities, that in the judgment of the investigator makes the subject unsuitable for standard dose induction chemotherapy (e.g., anthracycline and infusional cytarabine given as 7+3); or 3. Any patient age = 75 years. 3. Blast count = 20% (WHO criteria) 4. Greater than 25% of blasts must be CD33 positive. 5. Have a circulating blast count of less than 200/mm3 (control with hydroxyurea or similar agent is allowed); 6. Creatinine < 2.0 mg/dl 7. Estimated creatinine clearance = 50ml/min 8. Bilirubin = 2.0 mg/dl; AST and ALT < 5.0 times the ULN 9. Eastern Cooperative Oncology Group (ECOG) Performance Status = 2 Exclusion Criteria: 1. Patients with acute promyelocytic leukemia 2. Treatment with chemotherapy or biologic therapy within 3 weeks, except for hydroxyurea, which must be discontinued prior to treatment on study 3. Treatment with radiation within 6 weeks 4. Active serious infections uncontrolled by antibiotics 5. Active malignancy within 2 years of entry, except previously treated non-melanoma skin cancer, carcinoma in situ or cervical intraepithelial neoplasia, and organ confined prostate cancer with no evidence of progressive disease based on PSA levels and are not on active therapy. 6. Clinically significant cardiac or pulmonary disease 7. Patients with liver cirrhosis 8. Active CNS leukemia. Patients with symptoms of CNS involvement, particularly those with M4 or M5 subtypes, should undergo lumbar puncture prior to treatment on study to exclude CNS disease. Symptoms include cranial neuropathies, other neurologic deficits, and headache. 9. Psychiatric disorder that would preclude study participation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cytarabine (Phase 1 only)
Low dose cytarabine administered at 20 mg subcutaneously every 12 hours for the first 10 days (Days 1 to 10) of every cycle. Cycle 1 can last up to 52 days (depending on the schedule of study drug dosing) in order to allow for recovery from Lintuzumab-Ac225. Cycles 2-12 will last 28 days each.
Biological:
Lintuzumab-Ac225
In Phase 1 the starting dose level was 1.0 µCi/Kg of Lintuzumab-Ac225 and 15 µg/Kg unlabeled HuM195 divided into 2 equal fractionated doses (0.5 µCi/Kg and 7.5 µg /Kg + 0.5 µCi/Kg and 7.5 µg /Kg) with the first fraction administered approximately 4-7 days after 1 cycle of low dose cytarabine and the second fraction administered 4-7 days after the first fraction, followed by up to 11 more cycles. In Phase 2 the dose will be 4.0 µCi/Kg Lintuzumab-Ac225 and 25 µg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8.
Drug:
Furosemide (Phase 1 only)
40 mg by mouth daily one day prior to treatment with Lintuzumab-Ac225 and continuing for 10 days following administration of the 2nd divided dose.
Spironolactone
25 mg by mouth daily, administered 10 days after second dose of 225Ac-HuM195 and continued for 12 months.

Locations

Country Name City State
Puerto Rico VA Caribbean Healthcare System San Juan
United States Baylor Scott and White Research Institute, Charles A. Sammons Cancer Center Dallas Texas
United States Duke Cancer Center Durham North Carolina
United States St. Francis Cancer Center Greenville South Carolina
United States University of Kentucky, Markey Cancer Center Lexington Kentucky
United States UCLA Medical Center, Division of Hematology/Oncology Los Angeles California
United States University of Louisville, James Graham Brown Cancer Center Louisville Kentucky
United States Medical College of Wisconsin Cancer Center Milwaukee Wisconsin
United States West Virginia University, Mary Babb Randolph Cancer Center Morgantown West Virginia
United States Ochsner Medical Center, The Gayle and Tom Benson Cancer Center New Orleans Louisiana
United States Columbia University Medical, Herbert Irving Comprehensive Cancer Center New York New York
United States Memorial Sloan Kettering Cancer Center New York New York
United States Weill Medical College of Cornell University New York New York
United States University of Pennsylvania, Perelman Center for Advanced Medicine Philadelphia Pennsylvania
United States Mayo Clinic Rochester Minnesota
United States Fred Hutchinson Cancer Research Center Seattle Washington
United States Swedish Cancer Institute, Center for Blood Disorders and Stem Cell Transplantation Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Actinium Pharmaceuticals

Countries where clinical trial is conducted

United States,  Puerto Rico, 

References & Publications (3)

Jurcic JG, Rosenblat TL. Targeted alpha-particle immunotherapy for acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2014:e126-31. doi: 10.14694/EdBook_AM.2014.34.e126. — View Citation

Larson SM, Carrasquillo JA, Cheung NK, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015 Jun;15(6):347-60. doi: 10.1038/nrc3925. Erratum In: Nat Rev Cancer. 2015 Aug;15(8):509. — View Citation

Scheinberg DA, McDevitt MR. Actinium-225 in targeted alpha-particle therapeutic applications. Curr Radiopharm. 2011 Oct;4(4):306-20. doi: 10.2174/1874471011104040306. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Phase I: Maximum Tolerated Dose (MTD) of Lintuzumab-Ac225 If two or more patients in a cohort experience dose limiting toxicity (DLT), then maximum tolerated dose (MTD) will have been exceeded, and no further dose escalation will occur. If only three patients were treated at a dose level under consideration as the MTD, then up to three additional patients will be accrued. If no more than one of the six patients at that dose level experiences DLT, then that dose level will be confirmed as the MTD. Cycle 1, up to 52 days
Primary Phase II: CR+CRp+CRi The primary objective is to determine the antileukemic effects, including its ability to produce complete remissions, of Lintuzumab-Ac225. First evaluation at 42 days after treatment
Secondary Phase II: PFS Progression Free Survival 1 year
Secondary Phase II: LFS Leukemia Free Survival 1 year
Secondary Phase II: OS Overall Survival 1 year
Secondary Phase II: Toxicity Spectrum Safety Data 1 year
See also
  Status Clinical Trial Phase
Completed NCT03118466 - Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia Phase 2
Not yet recruiting NCT06313437 - Revumenib in Combination With 7+3 + Midostaurin in AML Phase 1
Withdrawn NCT03444649 - Epacadostat, Idarubicin and Cytarabine (EIC) in AML Phase 1
Withdrawn NCT02905994 - Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia Phase 1
Recruiting NCT02261779 - Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible Phase 1/Phase 2
Completed NCT00333190 - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation N/A
Completed NCT00246649 - Stem Cell Transplant With Specially Treated Cells in Treating Patients With Acute Leukemia N/A
Terminated NCT04079738 - Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib Phase 1/Phase 2
Completed NCT03466320 - DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 Phase 1/Phase 2
Withdrawn NCT03138395 - iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML N/A
Terminated NCT01570465 - Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients
Completed NCT04443751 - A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Phase 1
Terminated NCT03761069 - Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias Phase 1
Completed NCT02631993 - Photochemotherapy and Graft-versus-leukemia in Acute-leukemia N/A
Completed NCT00780598 - Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Phase 2
Completed NCT00863148 - Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) Phase 2
Completed NCT00761449 - Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5 Phase 2
Completed NCT00542971 - Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) Phase 1/Phase 2
Terminated NCT00176930 - Stem Cell Transplant for Hematological Malignancy N/A
Completed NCT00589082 - DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML Phase 3